Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SinoMab Bioscience Ltd. ( (HK:3681) ) has provided an announcement.
SinoMab BioScience Limited has entered into 26 subscription agreements with independent third-party subscribers to issue a total of 112,810,817 new shares at a price of HK$1.10 each. This move, which does not require shareholder approval, aims to raise approximately HK$124 million in gross proceeds, with net proceeds intended for strategic purposes outlined by the company. The issuance represents about 10.33% of the company’s current share capital and is expected to enhance SinoMab’s financial position and market presence.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, primarily engaged in the development of therapeutic drugs. The company focuses on the research and development of novel treatments for immunological diseases, leveraging its expertise in monoclonal antibody technology.
Average Trading Volume: 483,968
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.33B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue